Toggle navigation
About Us
Portfolio
News
Contact Us
Our venture capital fund focuses investments on early-stage life sciences companies looking to improve people’s outcomes with cancer.
Recent News
03/16/2022
C4 Therapeutics Appoints Utpal Koppikar to Board of Directors
READ MORE
03/15/2022
Wugen Announces First Patient Dosed in Phase 1/2 Trial of WU-CART-007 for the Treatment of Patients with R/R T-ALL/LBL
READ MORE
03/09/2022
Wugen to Present Virtually at the Upcoming Oppenheimer 32nd Annual Healthcare Conference
READ MORE
03/09/2022
C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma
READ MORE
03/03/2022
C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022
READ MORE
03/02/2022
NextRNA: small molecules take on lncRNA-protein interactions
READ MORE
03/01/2022
NextRNA Launches with $56 Million in Funding to Bring Transformative Non-Coding RNA-Directed Medicines to Patients
READ MORE
03/01/2022
NextRNA Launches with $56 Million in Funding to Bring Transformative Non-coding RNA-directed Medicines to Patients
READ MORE
02/24/2022
C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights
READ MORE
←
1
13
14
15
16
17
18
19
20
21
...
29
→
PORTFOLIO HIGHLIGHTS
Contact Us
Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131
Submit
4837,4748,4815,4823,4811,4819,4822,4748,4772,4748,4789,4811,4830,4819,4815,4760,4792,4760,4791,4825,4828,4817,4811,4824,4778,4825,4831,4830,4822,4825,4825,4821,4760,4813,4825,4823,4748,4758,4748,4829,4831,4812,4820,4815,4813,4830,4748,4772,4748,4781,4825,4824,4830,4811,4813,4830,4746,4784,4825,4828,4823,4748,4839
©2024 LIGHTCHAIN CAPITAL, LLC All Rights Reserved |
Privacy Policy
Website by
Tidal Media Group